Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.58 |
| ▸ | CMA1 | P23946 | 2/20 | 0.44 |
| ▸ | TDP2 | O95551 | 9/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | CASP9 | P55211 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16320760 | 0.81 | AHR (0.61) | AHRCMA1TDP2GRIA1CACNG8 | |
| SCHEMBL26666458 | 0.81 | AHR (0.47) | AHRCMA1TDP2PDK2GRM5 | |
| SCHEMBL25248436 | 0.78 | AHR (0.44) | AHRCMA1TDP2PDK2EIF2AK2 | |
| SCHEMBL31116942 | 0.78 | AHR (0.53) | AHRCMA1TDP2GRIA1CACNG8 | |
| SCHEMBL18289475 | 0.77 | AHR (0.59) | AHRCMA1TDP2PDK2EIF2AK2 | |
| SCHEMBL10951683 | 0.74 | AHR (0.45) | AHRCMA1TDP2GRIA1CACNG8 | |
| SCHEMBL1162926 | 0.73 | AHR (1.00) | AHRCMA1TDP2GRIA1CACNG8 | |
| SCHEMBL18554774 | 0.70 | AHR (0.53) | AHRCMA1TDP2PDK2GRM5 | |
| SCHEMBL19629850 | 0.70 | AHR (0.44) | AHRCMA1TDP2PDK2EIF2AK2 | |
| SCHEMBL9837197 | 0.70 | AHR (0.57) | AHRCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | disclosed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-8217044-B2 | Spiroindolinone pyrrolidines | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8088815-B2 | Spiroindolinone pyrrolidines | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011134925-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| US-20110269809-A1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN-LA ROCHE INC. | 2011-11-03 | — | — | US | disclosed |
| WO-2011067185-A1 | SPIROINDOLINONE PYRROLIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | BARTKOVITZ DAVID JOSEPH | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269809-A1 | SPIROINDOLINONE PYRROLIDINES | RB1, KRAS, PKD1 | AHR 1686/4885CMA1 4506/4885TDP2 2134/4885 |
| US-20110130398-A1 | SPIROINDOLINONE PYRROLIDINES | RPS4Y1, RB1, RPS4X | AHR 2051/4885CMA1 4582/4885TDP2 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.